Systemic therapy of bronchioloalveolar carcinoma: Results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma Journal Article

  


Authors: Kris, M. G.; Giaccone, G.; Davies, A.; Fukuoka, M.; Garfield, D. H.; Jassem, J.; Quoix, E. A.; Sandler, A. B.; Scagliotti, G. V.; Van Meerbeeck, J. P.; West, H.
Article Title: Systemic therapy of bronchioloalveolar carcinoma: Results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma
Abstract: INTRODUCTION: Bronchioloalveolar carcinoma (BAC) is a subtype of adenocarcinoma of the lung with unique pathological, clinical, and molecular characteristics. METHODS: This consensus conference group reviewed studies performed specifically in BAC and data from patients with BAC who were included in clinical trials of all non-small-cell lung cancer (NSCLC) subtypes. RESULTS: Although BAC as defined by the World Health Organization represents less than 5% of adenocarcinomas, as many as 20% of adenocarcinomas have BAC features. These latter tumors are more likely to have mutations in the epidermal growth factor receptor (EGFR) gene and to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib and erlotinib. Although most patients are men and have a history of smoking cigarettes, proportionally more are women and never smokers. Patients with BAC are routinely treated with drugs and regimens appropriate for patients with all subtypes of adenocarcinoma of the lung; four studies have been performed specifically in this disease. CONCLUSIONS: There is insufficient evidence to confirm or refute the assertion that the sensitivity of BAC to chemotherapy is different from that of other lung cancer histologic types. The unique clinical and molecular characteristics associated with BAC led this panel to conclude that future clinical trials should be designed specifically for persons with BAC. Recommendations for trial design and research questions are proposed. © 2006International Association for the Study of Lung Cancer.
Keywords: cancer chemotherapy; unclassified drug; gene mutation; major clinical study; clinical feature; clinical trial; cisplatin; doxorubicin; erlotinib; drug dose reduction; systemic therapy; conference paper; alpha interferon; paclitaxel; sensitivity analysis; adenocarcinoma; lung non small cell cancer; epidermal growth factor receptor; smoking; continuous infusion; protein p53; histology; protein tyrosine kinase inhibitor; lung adenocarcinoma; indometacin; gefitinib; lung alveolus cell carcinoma; world health organization; adenovirus vector; cancer classification; corticosteroid; granulocyte macrophage colony stimulating factor vaccine; hypoxemia; macrolide; lung infiltrate; respiratory tract disease; bronchioloalveolar carcinoma; sputum; cg 8123; bronchorrhea
Journal Title: Journal of Thoracic Oncology
Volume: 1
Issue: 9 Suppl.
ISSN: 1556-0864
Publisher: Elsevier Inc.  
Date Published: 2006-11-01
Start Page: S32
End Page: S36
Language: English
PROVIDER: scopus
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-34247884504&partnerID=40&md5=f9148b555ecffc317dfab8b0d3978943
Notes: --- - "Cited By (since 1996): 12" - "Export Date: 4 June 2012" - "Source: Scopus"